comparemela.com

Latest Breaking News On - Erdafitinib intravesical delivery system - Page 1 : comparemela.com

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.

United statesComunidad autonoma de catalunaVilaseca caboUrology serviceAmerican urological association annual meetingUrological association annualBacillus calmette guFgfr altered non muscle invasive bladder cancerNon muscle invasive bladder cancer2024 american urological association annual meeting2024 aua annual meetingTar 210Erdafitinib intravesical delivery system

TAR-210 results show 90 percent recurrence-free survival

Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor.

Comunidad autonoma de catalunaRegion flamandeSan antonioUnited statesEurop urolJanssen pharmaceuticaTanakam sonpavdeClin pharmacolSabine brookmanHenar heviaIndianj urolAstex therapeuticsDrug administrationEuropean medicines agencyNone of janssen cilag internationalEuropean society for medical oncology

First Results with Erdafitinib-Releasing Intravesical

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery.

Comunidad autonoma de catalunaRegion flamandeIndianj urolJanssen cilag gmbJanssen pharmaceuticaJeffrey infanteMartin vogelUrology care foundationJanssen research developmentNone of the janssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonEuropean society for medical oncologyAstex therapeuticsOncology early clinical developmentTranslational researchAstex announces new drug discovery alliance

Results from Phase 2 THOR-2 Study Showed Improved Rates of

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical.

Region flamandeUnited kingdomJanssen cilag gmbIndianj urolKiran patelJames wf cattoMartin vogelJanssen pharmaceuticaAstex announces new drug discovery allianceUniversity of sheffieldClinical developmentJanssen researchNone of the janssen pharmaceutical companiesExchange commissionJanssen pharmaceutical companiesDrug administration

Janssen Submits Marketing Authorisation Application to the

Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor,1 will become the.

United statesRegion flamandeJanssen pharmaceuticaTanakam sonpavdeKiran patelJanssen cilag gmbMartin vogelClinical developmentJanssen pharmaceutical companiesAstex therapeuticsAstex announces new drug discovery allianceAmerican society of clinical oncologyNone of the janssen pharmaceutical companiesCompanies of johnsonJanssen research development in phaseJanssen research development

vimarsana © 2020. All Rights Reserved.